Irinotecan
Irinotecan 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Pancreatic Cancer、Metastatic Pancreatic Cancer、Metastatic Pancreatic Adenocarcinoma、Gastric Cancer。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
4 项
已进入 III/IV 期
15 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Astellas Pharma Global Development, Inc.
- AstraZeneca
- Chinese PLA General Hospital
- Reema A. Patel
- UNC Lineberger Comprehensive Cancer Center
- Fudan University
- National Cancer Institute, Naples
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
中国、美国、意大利、澳大利亚、法国、奥地利、比利时、Czechia、丹麦、Greece、爱尔兰、Israel
正在招募患者的 Irinotecan 研究
Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.
II 期招募中中国NCT07044921GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
不适用招募中美国NCT05391126Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
I 期 / II 期招募中美国NCT06483555Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
II 期招募中中国NCT06928584Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
III 期招募中意大利NCT06509126Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU
II 期招募中中国NCT07391618NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
II 期招募中中国NCT06405490Liposomal Irinotecan and Apatinib in ES-SCLC
II 期招募中中国NCT06749691I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
II 期招募中美国NCT01042379Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
I 期招募中美国澳大利亚NCT06974110sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
II 期招募中美国NCT05332002Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
不适用招募中美国NCT04199026Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
II 期招募中美国NCT07201519DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer
II 期招募中法国NCT06757244Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial
II 期招募中中国NCT07106034UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer
IV 期招募中中国NCT05148767A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
III 期招募中中国NCT03303495FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
I 期 / II 期招募中澳大利亚奥地利比利时CzechiaNCT04625907Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
I 期 / II 期招募中中国NCT05319639Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
III 期招募中美国加拿大NCT06958328Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer
II 期招募中中国NCT06184698Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease
I 期 / II 期招募中美国NCT07346157Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
II 期招募中中国NCT06540326New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer
II 期招募中中国NCT07559760
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。